BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...therapy is a biosimilar of anti-HER2 mAb Herceptin trastuzumab. Chinese approval for Ascletis HCV combo Ascletis...
...Inc. Eli Lilly and Co. Mirati Therapeutics Inc. Amgen Inc. Merck & Co. U.S. Food and Drug Administration (FDA) Truvian Sciences Inc. Ascletis...
BioCentury | May 23, 2020
Finance

Proposed legislation could deter Chinese biotechs from listing in U.S.

...among the five life sciences companies who lost more than 8%: Hua Medicine Ltd. (HKEX:2552), Ascletis...
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

...scarcity value of companies in growth sectors including biotech. However, the poor aftermarket performance of Ascletis...
...at a $2 billion valuation in July 2018. The step-up of the IPO price from Ascletis’...
...traded down 50% within the first two weeks of listing, and has yet to recover; Ascletis...
BioCentury | Apr 8, 2020
Product Development

Pushing limits of detection for the new coronavirus

...'cured'? Detection sensitivity is critical." Jinzi Wu, Ascletis   Jinzi Wu, chairman and CEO of Ascletis...
...95.6%. Source: Manufacturers' instructions for use documents Karen Tkach Tuzman, Associate Editor U.S. Food and Drug Administration (FDA) Ascletis...
BioCentury | Apr 1, 2020
Product Development

The Race Is On: Strategies for COVID-19 Product Development

...conducting such trials in the midst of an epidemic. Jinzi Wu, chairman and CEO of Ascletis...
...world. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . BioCentury Staff Regeneron Pharmaceuticals Inc. Ascletis...
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

...in North America and Europe. Latest Ascletis data In a preprint posted to medRxiv , Ascletis...
...https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) Grifols S.A. Vir Biotechnology Inc. Xencor Inc. Ascletis...
BioCentury | Mar 19, 2020
Product Development

Slotting anti-inflammatories into COVID-19 treatment

...Other antivirals under evaluation for the infection include lopinavir/ritonavir and HCV drug Ganovo danoprevir from Ascletis...
...Wuhan, China. Ganovo has produced positive results, although the trial excluded patients with severe disease. Ascletis...
...satisfying discharge criteria under “Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6)." Ascletis’...
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

...processes viral proteins required for SARS-CoV-2 replication, are in clinical trials for COVID-19: ASC09F from Ascletis...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

...Eleven COVID-19 patients discharged after receiving Ascletis drug Ascletis Pharma Inc. (HKEX:1672) said all 11 COVID-19...
...Health Commission. Ganovo, a protease inhibitor, received NMPA approval in 2018 to treat HCV (see “Ascletis...
...Myostatin VEGF - Vascular endothelial growth factor BioCentury Staff Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) ACE-083 ABP-100 ABP-201 Ascletis...
BioCentury | Feb 27, 2020
Product Development

COVID-19 roundup: Qiagen ships diagnostic to China; plus Gilead starts own remdesivir trials and Ascletis clinical update

...to treat COVID-19, bringing the total number of trials testing the antiviral to five, and Ascletis...
...trials of remdesivir in Hubei; data are expected in April. Patients receiving Ascletis' drug discharged Ascletis...
...Assistant Editor Sandi Wong contributed to this report Elizabeth S. Eaton, Staff Writer remdesivir, GS-5734 Qiagen N.V. Gilead Sciences Inc. COVID-19 SARS-CoV-2 Ascletis cov19count cov19count...
Items per page:
1 - 10 of 151
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...therapy is a biosimilar of anti-HER2 mAb Herceptin trastuzumab. Chinese approval for Ascletis HCV combo Ascletis...
...Inc. Eli Lilly and Co. Mirati Therapeutics Inc. Amgen Inc. Merck & Co. U.S. Food and Drug Administration (FDA) Truvian Sciences Inc. Ascletis...
BioCentury | May 23, 2020
Finance

Proposed legislation could deter Chinese biotechs from listing in U.S.

...among the five life sciences companies who lost more than 8%: Hua Medicine Ltd. (HKEX:2552), Ascletis...
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

...scarcity value of companies in growth sectors including biotech. However, the poor aftermarket performance of Ascletis...
...at a $2 billion valuation in July 2018. The step-up of the IPO price from Ascletis’...
...traded down 50% within the first two weeks of listing, and has yet to recover; Ascletis...
BioCentury | Apr 8, 2020
Product Development

Pushing limits of detection for the new coronavirus

...'cured'? Detection sensitivity is critical." Jinzi Wu, Ascletis   Jinzi Wu, chairman and CEO of Ascletis...
...95.6%. Source: Manufacturers' instructions for use documents Karen Tkach Tuzman, Associate Editor U.S. Food and Drug Administration (FDA) Ascletis...
BioCentury | Apr 1, 2020
Product Development

The Race Is On: Strategies for COVID-19 Product Development

...conducting such trials in the midst of an epidemic. Jinzi Wu, chairman and CEO of Ascletis...
...world. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . BioCentury Staff Regeneron Pharmaceuticals Inc. Ascletis...
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

...in North America and Europe. Latest Ascletis data In a preprint posted to medRxiv , Ascletis...
...https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) Grifols S.A. Vir Biotechnology Inc. Xencor Inc. Ascletis...
BioCentury | Mar 19, 2020
Product Development

Slotting anti-inflammatories into COVID-19 treatment

...Other antivirals under evaluation for the infection include lopinavir/ritonavir and HCV drug Ganovo danoprevir from Ascletis...
...Wuhan, China. Ganovo has produced positive results, although the trial excluded patients with severe disease. Ascletis...
...satisfying discharge criteria under “Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6)." Ascletis’...
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

...processes viral proteins required for SARS-CoV-2 replication, are in clinical trials for COVID-19: ASC09F from Ascletis...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

...Eleven COVID-19 patients discharged after receiving Ascletis drug Ascletis Pharma Inc. (HKEX:1672) said all 11 COVID-19...
...Health Commission. Ganovo, a protease inhibitor, received NMPA approval in 2018 to treat HCV (see “Ascletis...
...Myostatin VEGF - Vascular endothelial growth factor BioCentury Staff Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) ACE-083 ABP-100 ABP-201 Ascletis...
BioCentury | Feb 27, 2020
Product Development

COVID-19 roundup: Qiagen ships diagnostic to China; plus Gilead starts own remdesivir trials and Ascletis clinical update

...to treat COVID-19, bringing the total number of trials testing the antiviral to five, and Ascletis...
...trials of remdesivir in Hubei; data are expected in April. Patients receiving Ascletis' drug discharged Ascletis...
...Assistant Editor Sandi Wong contributed to this report Elizabeth S. Eaton, Staff Writer remdesivir, GS-5734 Qiagen N.V. Gilead Sciences Inc. COVID-19 SARS-CoV-2 Ascletis cov19count cov19count...
Items per page:
1 - 10 of 151